Foot-and-mouth disease virus FMDV A24/Cruzeiro/BRA/55 Recombinant human adenovirus vectored vaccine DIVA Vaccine efficacy Adjuvant a b s t r a c t A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/ Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL Ò adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL Ò adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days postvaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL Ò at the same dose used in the first study, followed by FMDV A24/ Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration of AdtA24 formulated in ENABL Ò adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.
Introduction
Foot-and-mouth disease (FMD) is the most contagious infection in livestock [1, 2] . FMD virus (FMDV), an Aphthovirus in the Picornaviridae, causes significant agro-economic loss throughout many parts of the world [1] . FMDV infects cloven-hoofed animals, including cattle, domestic and feral swine, sheep, goats, and buffalo [2] . There are seven FMDV serotypes, and multiple subtypes within each serotype [2] . FMD is enzootic in Africa and Asia [2] , and at least 15 other countries in Asia, northern Africa, South America, and Europe have reported sporadic outbreaks [3] . In FMD-free https://doi.org/10.1016/j.vaccine.2018.01.026 0264-410X/Ó 2018 Published by Elsevier Ltd.
Abbreviations: AdtA24, replication-deficient human adenovirus vectored FMDV A24/Cruzeiro/BRA/55 vaccine; APHIS, Animal and Plant Health Inspection Services; CVB, Center for Veterinary Biologics; DIVA, differentiate infected from vaccinated animals; dpc, days post-challenge; dpv, days post-vaccination; FFB, final formulation buffer; FMD, foot-and-mouth disease; FMDV, foot-and-mouth disease virus; GMT, geometric mean VNT titer; NSP, nonstructural protein; PU, particle units; USDA, United States Department of Agriculture; VNT, virus neutralization test.
countries, recent outbreaks resulted in economic impacts of >$2.8-16 billion [1, 4, 5] .
To prevent FMD outbreaks in enzootic countries, semi-annual vaccination using chemically inactivated FMDV, purified from large in vitro cell culture batches is often practiced [6] . To prepare for an accidental or intentional FMD outbreak in the United States and enable production of FMD vaccine on the mainland without using FMDV, we developed a replication-defective human adenovirus serotype 5 molecular vaccine platform designed to deliver FMDV capsid and capsid processing genes [7] [8] [9] . To produce FMD molecular vaccines to match circulating viral strains, the only information required is the nucleic acid sequence of the capsid coding region of the target strain(s), which can be chemically synthesized and inserted into the adenovirus vector (adenovector). Cattle and pigs vaccinated with various adenovectored FMD experimental vaccines were protected from clinical FMD following challenge with the homologous FMDV strain [7, [10] [11] [12] [13] .
One version of the adenovectored vaccine, AdtA24, comprises the FMDV A24/Cruzeiro/BRA/55 P1-2A coding region, plus part of FMDV A12/119/Kent/UK/32's 3B1, and full 3B2, 3B3, and 3C coding regions [8, 9, 13] . AdtA24 does not replicate in the vaccinated animal [14] . Only the mRNA for the FMDV capsid proteins is expressed and processed, initially in the muscle cells at the injection site, followed by antigen presentation to the immune system in local draining lymph nodes, and eventually in additional lymph nodes, the liver, spleen, and thymus [14] .
Previously we demonstrated that AdtA24 administered at relatively high doses without adjuvant prevented clinical FMD and viremia in immunized steers challenged at either 7 or 14 days postvaccination (dpv) [13] . To support our goal to lower the vaccine cost we formulated AdtA24 with several adjuvants and conducted preliminary cattle serology studies (data not shown). The most promising adjuvant, a lipid/polymer, ENABL Ò , was formulated with AdtA24 for evaluation of efficacy in cattle challenged via the intradermolingual (IDL) route with FMDV A24/Cruzeiro/BRA/55. Results from our first study demonstrated that addition of this ready-to-use ENABL Ò adjuvant resulted in protection at a 19-fold lower dose than the predicted 90% effective dose of AdtA24 prepared in buffer [13] . The second of our studies reported herein was designed to meet the United States Department of Agriculture (USDA) Animal and Plant Health Inspection Services (APHIS) Center for Veterinary Biologics (CVB) guidelines to fulfill requirements to obtain a product license.
Our goal is to have effective molecular FMD vaccine formulations that are economically attractive, can be manufactured in United States biosafety level-2 facilities, deployed rapidly in the event of an outbreak, and differentiate infected from vaccinated animals (DIVA) against the highest FMDV global threats.
Materials and methods

Animals
An accredited experimental-livestock provider supplied healthy, 200-250 kg Holstein steers, 9-11½ months old. Prior to vaccination, we allocated steers randomly to treatment groups where they moved freely about their biosafety level-3 room. There was no concomitant medication during the studies or the 5-7 day acclimation period. The second study was designed to evaluate a single, adjuvanted vaccine dose to meet the USDA APHIS CVB pivotal immunogenicity study design requirements for vaccine licensure using a 14 dpv challenge model. At 14 days before challenge, AdtA24 was prepared in ENABL Ò adjuvant + FFB at 2.7 Â 10 9 PU/dose for T3, n = 34 steers in two rooms, and six steers in C2 in a different room, were sham-immunized (ENABL Ò + FFB). Although not required by USDA APHIS CVB, T4 (n = 10) received the same dose of AdtA24 vaccine, 7 days prior to challenge, to understand the early onset of protection at the AdtA24 vaccine minimum protective dose.
(T4 was limited in size due to available space.)
Preparation of FMDV challenge
At 7 or 14 dpv (designated per protocol), we challenged sedated steers according to the OIE guidelines via the intradermolingual (IDL) route using FMDV A24/Cruzeiro/BRA/55 stock produced and titrated in bovine tongue [13, 16] . The challenge dose was 1 Â 10 4 bovine infectious dose 50%/0.4 mL, with titers ranging from 5.625 to 6.0 log 10 tissue culture infective dose 50% (TCID 50 )/mL after back titration of inocula on LFBK-a V b 6 cells, kindly provided by M. LaRocco, USDA Agricultural Research Service, PIADC [17, 18] . All samples collected on the day of challenge occurred prior to FMDV inoculations.
Blinding of immunizations, clinical observations (pedal lesions), and laboratory analyses occurred through masked treatment allocation. The primary outcome included the prevention of clinical FMD and lesion development on hooves, assessed on 3, 7, 10, and 14 days post-challenge (dpc) [13] .
Serum virus neutralization test (VNT)
Serum samples from each steer were collected weekly prior to administration of any treatments starting on the day of vaccination. Antibody titers to FMDV A24/Cruzeiro/BRA/55 and to adenovirus serotype 5 (Ad5) were determined by VNT using heat-inactivated serum samples (56°C, 30 min) [ ) cells. VNT titers were calculated using the Spearman-Kärber method based on cytopathic effect (CPE) using 50% as the neutralization endpoint. A positive VNT titer was >0.6 log 10 , and the percent positive was the fraction of serum samples with VNT titers >0.6 log 10 . The lower limit of detection, 0.6 log 10 , was used for calculations of samples with no CPE [10, 19] .
2.7. Detect antibody production to the FMDV 3ABC non-structural protein (NSPs)
The PrioCHECK Ò FMDV NS blocking ELISA (ThermoFisher Scientific) was used to detect antibodies to the nonstructural 3ABC protein, per manufacturer's instructions. A positive serum sample has !50% inhibition.
FMDV detection in plasma and nasal secretions
Heparinized blood (plasma) samples collected on 0-5 dpc from all steers were tested for the presence of infectious FMDV on LFBKa v b 6 cells [13, 16] and for the presence or absence of FMDV RNA by rRT-PCR [16, 20] . RNA was extracted using the MagMAX TM Viral RNA Isolation Kit (ThermoFisher Scientific). A C t value 40 was scored positive. A positive result in either test was scored as viremia. In Study 2, per USDA APHIS CVB regulatory feedback on Study 1 results, we collected nasal swabs (polyester fiber) prior to challenge on 0 dpc and daily on 1-8 dpc, and detected infectious FMDV on LFBK-a v b 6 cells [13] . The limit of detection for FMDV from nasal secretions was 1.5 log 10 TCID 50 /mL.
Data analysis
For the positive virus isolation data obtained from nasal swabs in Study 2, we determined daily (2, 3, and 4 dpc) mean and standard deviation of FMDV titers (TCID 50 /mL) for each group. VNT titers were analyzed using unpaired two-tailed T-tests (Welch correction; Excel and GraphPad). Other analyses used the Fisher's Exact Test (GraphPad). For all analyses, a P .05 was considered statistically significant.
Results
Efficacy study 1. Comparison of AdtA24 vaccine formulated with or without adjuvant inoculated into steers and challenged at 14 dpv
In the first study, we assessed the effect of AdtA24 formulated with and without an adjuvant on prevention of clinical FMD and viremia and on the production of functional neutralizing antibodies to FMDV and the adenovector ( Table 1 ). All five C1 control steers developed clinical FMD and viremia. Lesions developed on all four hooves of all non-vaccinated controls by 3 dpc. All 10 steers in T2 (3.0 Â 10 9 PU + ENABL Ò adjuvant) were protected from both generalized FMD and viremia compared to 82% of 22 steers in T1 (1.2 Â 10 10 PU in FFB). Protection from clinical FMD and viremia for T1 and T2 were not different from each other (P = .28), but were different from results in C1 (P < .01). Due to the relatively high protection against viremia in both T1 (82%) and T2 (100%) differences in onset to viremia could not be assessed.
The percentage of steers with positive VNT titers to FMDV A24/ Cruzeiro/BRA/55 was greater for T2 (90%) than for T1 (64%) steers on the day of challenge (14 dpv), but not statistically significant (P = .2) ( Table 1 ). The geometric mean FMDV VNT titers (GMTs) for the T2 steers were significantly higher compared to the T1 steers on both 7 dpv (P = .04) and 14 dpv (P = .009) (Fig. 1A and Table 1 ).
By 7 and 14 dpc, the GMTs to FMDV for all groups were !2.2 and !2.5 log 10 (Fig. 1A) .
The adenovirus GMT increased from 7 to 14 dpv by >10-fold for the AdtA24 plus adjuvant group (T2) and remained at that level through 14 dpc (Fig. 1B) . The adenovirus GMT was significantly higher in T2 steers compared to T1 steers; P < .001 for serum samples collected at 14, 21, or 28 dpv (Fig. 1B). 3.2. Efficacy study 2. Evaluation of steers vaccinated with AdtA24 formulated in ENABL Ò adjuvant and challenged at 7 or 14 dpv
In the second study, the same adjuvanted vaccine dose that was effective in the first study was administered to two groups of steers, challenged at 14 or 7 dpv (T3 and T4). Protection from clinical FMD for steers challenged at 14 dpv was similar between both studies for the AdtA24/ENABL Ò T2 and T3 groups ( Table 1 ). All 10 steers challenged at 7 dpv (T4) were protected from clinical FMD. Unexpectedly, one of the six control steers in C2 did not develop FMD (Table 1 ), but the other five control steers developed lesions on all hooves by 3 dpc. Protection from clinical FMD and viremia was significantly different between C2 and each of the vaccination groups (P < .01), but not between T3 and T4 (P > .99).
During the first 5 dpc, viremia was prevented in 91% and 90% of the steers in the T3 and T4 vaccine groups (Table 1) ; therefore, differences in onset to viremia could not be evaluated. In C2, five naïve steers were positive for viremia on 1-3 dpc, and four remained positive at 4 dpc (data not shown). The C2 calf that was free of clinical FMD and viremia developed lesions only on the tongue and antibodies to FMDV (1.2 log 10 ) and the FMDV NSPs by 7 dpc, indicating that this steer may not have received a sufficient challenge.
Prior to challenge (0 dpc) and on 5-8 dpc, all samples from each steer were negative for FMDV in nasal secretions. Nasal shedding of FMDV occurred on 1-4 dpc (Fig. 2) . The prevalence of nasal shedding over 1-4 dpc was significantly lower in T3 (17%, 23/136) and T4 (23%, 9/40) compared to C2 (63%, 15/24) (P .003). The positive FMDV titers in C2 secretions on 1-4 dpc were statistically different from those in either T3 or T4 (P .02). However, there was no difference between T3 and T4 on 1-4 dpc (P = .3). Additionally, 67% of both T3 and T4 vaccinates were FMDV positive on 2 dpc, suggesting that the time between vaccination and challenge did not impact the onset of nasal shedding.
The GMT to FMDV A24/Cruzeiro/BRA/55 was higher on the day of challenge for T3 (14 dpv/0 dpc) than for T4 (7 dpv/0 dpc)), and the GMTs were significantly different (P = .005) (Fig. 3A and Table 1 ). At 7 dpv, there was a significant difference between the VNT titers in C2 compared to either T3 or T4 (P < .001 and P = .03). However, there was no difference between the FMDV VNT titers at 7 dpv for T3 compared to T4 (P = .96). All steers had positive FMDV VNT titers by 7 dpc. By 7 dpv, 94% of the T3 samples were positive by VNT to the adenovector, and all were positive at 14, 21, and 28 dpv. Similarly, all T4 samples were positive for antibodies to the adenovector by 7 dpv/0 dpc, and remained positive through 14 dpc. There were no significant differences between the adenovector VNT titers in T3 compared to T4 at 7, 14, and 21 dpv (Fig. 3B) . No antibodies to the adenovector were detected in control steers, despite being co-mingled with 44 vaccinated steers for 21 or 28 days.
Differentiation of infected from vaccinated animals (DIVA)
No vaccinated steers produced antibodies to the FMDV 3ABC NSPs prior to challenge in either study (Fig. 4A and B) . In Study 1, all five control steers (C1) were positive for antibodies to the NSPs by 7 dpc, while 45% and 30% of the steers in T1 and T2 were positive, which increased by 14 dpc for T1 (73%) and T2 (60%) (Fig. 4A) . In Study 2, all C2 and T4 steers were positive for antibodies to the NSPs on 7 dpc, and 53% and 85% of T3 steers were positive on 7 and 14 dpc (Fig. 4B ).
Discussion
In two studies, we evaluated the effectiveness of single dose vaccination of steers with AdtA24 formulated with the adjuvant, ENABL absence of an injection site and gross physical reaction, lack of febrile response within the first three days, and lack of vaccine vector shedding (data not shown; consistent with previous results [13, 21] ). The AdtA24/ENABL Ò post-vaccination/pre-challenge antigenicity (FMDV A24/Cruzeiro/BRA/55 VNTs) and efficacy results are higher and more consistent versus our previous reported findings with AdtA24 vector alone [13, 21] . The antigenicity and efficacy results reported herein using the AdtA24/ENABL Ò formulation are consistent with results using a related adenovirus vector expressing the FMDV A24/Cruzeiro/BRA/55 capsid coding region [12] or the FMDV O coding region [22] . Other adenovirusvectored FMD vaccines using FMDV serotype A, O, or Asia capsid coding regions, administered at 5 Â 10 9 plaque forming units/dose (approximately 5 Â 10 10 PU), elicited FMDV VNT titers at 14 dpv that were lower than the current study, although VNT titers to the adenovirus vector were similar [23] . Our antigenicity and efficacy results are similar to reported results using conventional inactivated vaccines [24] [25] [26] [27] . The AdtA24/ENABL Ò formulation, administered 7 or 14 days before challenge, reduced the estimated 90% bovine protective dose (BPD 90) by 19-fold compared to the estimated BPD 90 of 5.6 Â 10 10 PU for AdtA24 without adjuvant administered 7 days before Geometric mean VNT titers ± standard deviation for each treatment group at each time are presented. Differences between the FMDV A24/ Cruzeiro/BRA/55 (A) results obtained on 7 dpv and 14 dpv/0dpc for the VNT titers in T1 and T2 were statistically significant (P = .04; P = .009). Differences between the adenovirus serotype 5 (B) results obtained on 14 dpv/0dpc, 21 dpv/7 dpc, and 28 dpv/14 dpc for the VNT titers in T1 and T2 were statistically significant (P < .001 for each). The range of positive values for both assays was >0.6-3.3 log 10 . The dotted line represents the limit of detection for the assay, 0.6 log 10 .
IDL challenge [13] . Similarly 3 Â 10 9 PU AdtA24/ENABL Ò prevented 90-100% of viremia, one-tenth the estimated BPD 90 of 3 Â 10 10 PU for AdtA24 alone [13] . Based on the estimated minimum protective dose for other Adt-vectored serotype A and O subtypes formulated in ENABL Ò that we have tested (manuscript in preparation), we speculate that future studies will demonstrate a lower minimum protective dose of AdtA24/ENABL Ò with > 90% efficacy. Another compound acting as an adjuvant, poly ICLC, lowers the protective dose for a related Ad5-A24 FMD vaccine [28] . The postulated mechanism of AdtA24 vaccine protection against homologous challenge involves the presentation of assembled FMDV A24/Cruzeiro/BRA/55 empty capsids or virus like particles to the host. We speculate that the AdtFMD expressed empty capsids are highly similar to the viral capsids present in current chemically inactivated and purified FMDV vaccines, and thus may share some of their reported intra-serotype cross-reactivity and protection attributes. For example, cross-protection in cattle among various chemically inactivated FMDV serotype A monovalent vaccines at full dose approached 100% against A22Iraq, AIran99, AIran96, and AEgytp06 [25] . However, ¼ and 1/16 of the prescribed full dose resulted in 0-80% protection against the heterologous strain [25] .
Although the immune response to the adenovirus vector was higher in the groups with adjuvant, we do not expect an antagonistic outcome following revaccination with the same vector. For example, two cattle that were vaccinated and boosted 9 weeks later with the same dose of Ad5-A24 developed high serum antibody response to FMDV and did not develop clinical FMD, while the control cattle had severe clinical FMD [29] . When other cattle were re-vaccinated with a bovine adenovirus 3-vectored vaccine or an adenovirus 5-vectored vaccine, there were no adverse effects on the immune response [23, 30] .
The DIVA capability of the AdtA24 vaccine was confirmed in these studies, as previously reported [13, 21] . Although the AdtA24 vaccine construct contains part of the FMDV NSP coding regions: 3B1, minus the coding region for the first six amino acids, and the complete 3B2, 3B3, and 3C coding regions, no antibodies were detected until 7 dpc in control, non-vaccinated steers and by 7-14 dpc in AdtA24-vaccinated steers. Sera from non-vaccinated FMDVinfected animals are usually positive by 7 days post challenge [13, 31, 32] (Chung, submitted; unpublished results). Because FMDV has some local replication in the tongue following the IDL inoculation, adenovirus vectored FMD or inactivated FMDV vaccinated, FMDV-challenged cattle develop antibodies to the NSPs [12, 32] . The PrioCHECK Ò FMDV NS ELISA uses a monoclonal antibody to an unspecified epitope of FMDV 3B [33] [34] [35] , presumably to 3B1, including at least part of the deleted 3B1 coding region in AdtA24 (personal communication). Administration of the related adenovirus vector with FMDV capsid P1-2A and 3C protease coding regions to cattle or swine does not elicit a positive response in the PrioCHECK Ò assay prior to infection, indicating that antibodies to FMDV 3C protein are not recognized [11, 12] . Therefore, AdtA24 does not contain the coding region for the epitopes recognized by Cruzeiro/BRA/55 (A) results obtained on 7 dpv (À7 dpc) for C2 and T3, and for C2 on 14 dpv (0 dpc) and T4 on 7 dpv (0 dpc) were statistically significant (P < .001 and P = .03), and the 7 dpv data for T3 (À7 dpc) and T4 (0 dpc) were not different (P = .96). Differences between the adenovirus serotype 5 (B) results obtained on 7 dpv (À7 dpc) for C2 and T3, and for C2 on 14 dpv (0 dpc) and T4 on 7 dpv (0 dpc) were statistically significant (P < .001 for each). The 7, 14, and 21 dpv data for T3 and T4 were not different (P = .14, P = .11, and P = .32). The range of positive values for both assays was 0.6-3.3 log 10 . The dotted line represents the limit of detection for the assay, 0. [33, 36] .) Using a different FMDV 3B ELISA (VMRD, Inc.) with a high correlation to results with the Prio-CHECK Ò FMDV NS ELISA, no antibodies to FMDV 3B NSPs were detected in 52 AdtFMD-vaccinated cattle and pigs at 7-29 dpv (Chung, manuscript submitted). On a longer term, at 9-10 months after AdtA24 vaccination, uninfected cattle were negative in the newer FMDV 3B ELISA, although they were positive for antibodies to the FMDV A24/Cruzeiro/BRA/55 capsid proteins and adenovirus vector [21] . Future research involves developing effective molecular FMD vaccines with or without an adjuvant for pigs. In our laboratory, using an oro-pharyngeal FMDV swine challenge model [37, 38] , AdtA24/ENABL Ò vaccine conferred 80% efficacy against clinical FMD, a result identical to that using a commercial FMDV A24/Cruzeiro/BRA/55 vaccine (unpublished results). However, this same AdtA24/ENABL Ò vaccine dose was ineffective in pigs challenged via the intradermal heel bulb route. We are currently collaborating with federal and industry scientists to improve AdtFMD antigenicity and efficacy in swine. Licensed FMD vaccines used worldwide are made from tissue culture adapted field isolates that are amplified, chemically inactivated, purified, and typically formulated with aqueous adjuvants (aluminum hydroxide/saponin) or as an oil emulsion (water-inoil or water-in-oil-in water) [39] [40] [41] . Adjuvants used with inactivated FMDV vaccines enhance storage stability, provide a good antibody response, improve protection, and can shorten onset of protection [26, [42] [43] [44] [45] . Our results demonstrated that the addition of a ready-to-use adjuvant, ENABL Ò , with the recombinant AdtA24 DIVA FMD vaccine, lowered the cattle minimum protective dose and increased the antibody response significantly compared to AdtA24 alone, to provide a cost effective FMD vaccine. 
